Christopher Jayne, MD
Obstetrics & Gynecology · Houston, TXNPI 1316908494
Payments from drug & device makers
Across 156 payments — averaging $330.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$16K
- Medical Device Business Services, Inc.$15K
- Johnson & Johnson$10K
- Boston Scientific$6K
- Scynexis, Inc.$1K
- Medtronic$1K
- plus $3K from 22 others
Across 1 payment — averaging $2550.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- New View Surgical, Inc.$3K
What the payments were for
- Consulting fees$25,62050%
- Speaking & faculty fees$4,5059%
- Travel & lodging$1,0192%
- Food & beverage$5,66011%
- Education$14,69929%
- Gifts$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 23 | $15,676 |
| Medical Device Business Services, Inc. | 8 | $14,558 |
| Johnson & Johnson(2 entities) | 9 | $10,292 |
| Boston Scientific | 17 | $5,656 |
| Scynexis, Inc. | 2 | $1,132 |
| Medtronic(2 entities) | 14 | $1,011 |
| Caldera Medical, Inc | 15 | $782 |
| New View Surgical, Inc. | 1 | $471 |
| Astellas Pharma US Inc | 16 | $408 |
| Coopersurgical, Inc. | 4 | $273 |
| Axonics, Inc. | 8 | $265 |
| Convatec Inc. | 4 | $209 |
| Pfizer | 9 | $159 |
| Pacira Pharmaceuticals Incorporated | 1 | $118 |
| Sumitomo Pharma America, Inc. | 5 | $113 |
| Hologic Sales And Service, LLC | 3 | $98 |
| 180 Medical, Inc. | 4 | $73 |
| Urovant Sciences Inc | 2 | $45 |
| Antares Pharma, Inc. | 2 | $31 |
| AbbVie | 1 | $23 |
| Olympus America Inc. | 1 | $22 |
| Smith+Nephew | 1 | $22 |
| Therapeuticsmd, Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $20 |
| Coloplast | 1 | $18 |
| BD | 1 | $17 |
| Renovia Inc | 1 | $15 |
| Kerecis Limited | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Harmonic$22,324
- STRATAFIX$17,037
- DAVINCI XI$14,500
- UPSYLON$4,614
- HARMONIC Product Family$2,322
- Da Vinci Surgical System$911
- INTERSTIM$653
- VisionPort$471
- Solyx SIS System$374
- Desara$348
- Uterine Manipulators & Injectors$225
- GENERAL - THERAPIES$150
- Advantage System$138
- Vertessa$136
- ECHELON FLEX Stapler$122
- GENERAL FEMALE SUI$120
- EXPAREL$118
- SOLYX$110
- CURE TWIST$103
- Axonics$101
How this compares
$51,536 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 54 | $29,776 |
| PremarinEstrogens, Conjugated | 28 | $12,767 |
| Estradiol | 57 | $2,754 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 34 | $796 |
| Solifenacin Succinate | 25 | $697 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $311 |
| Hydroxyzine Hcl | 11 | $82 |
| Tramadol Hcl | 56 | $78 |
| Darifenacin ErDarifenacin Hydrobromide | 11 | $68 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $408 | $29,77654 claims |
| PfizerPremarin | $159 | $12,76728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Houston
- Amir JazaeriHouston$19.5M
- Shannon WestinHouston$17.3M
- Mark JacobsHouston$2.8M
- Sandra HurtadoHouston$1.7M
- Dawn BlackHouston$1.2M
- George KuhnHouston$244K
- Luis Sandoval-MartinezHouston$234K
- Daisy AyimHouston$188K
- Asha BhalwalHouston$151K
- Monica LopezFort Worth$8.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.